CLINICAL_TRIALS
trial_result
· 2019-09-24
Clinical Trial Update: Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus [Phase 2]
Summary
Phase 2 trial update reporting dose response for Dance 501 in subjects with Type 2 Diabetes Mellitus.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dance Biopharm Inc. | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED